13 active trials 6 recruiting 4 Phase 3 10 disease areas
| Phase 1 | 3 | |
| Phase 1/2 | 2 | |
| Phase 2 | 4 | |
| Phase 2/3 | 2 | |
| Phase 3 | 2 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT07128199 | A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With… | Lung Cancer | Active, Not Recruiting | 2026-08-26 |
| NCT05973773 | REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) | Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation | Active, Not Recruiting | 2026-07-30 |
| Phase 2/3 | ||||
| NCT04256317 | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone… | Myelodysplastic Syndromes | Recruiting | 2026-04-30 |
| NCT06506955 | Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy… | Advanced/Metastatic Cancer | Active, Not Recruiting | 2026-07-28 |
| Phase 2 | ||||
| NCT05727176 | Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or… | Advanced Cholangiocarcinoma | Recruiting | 2026-09-01 |
| NCT05967689 | A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With… | Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations | Recruiting | 2026-09-01 |
| NCT05945823 | Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid… | Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer | Active, Not Recruiting | 2026-09-01 |
| NCT04093570 | A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard… | Acute Myeloid Leukemia | Enrolling by Invitation | 2026-07-28 |
| Phase 1/2 | ||||
| NCT04657081 | Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute… | Acute Myeloid Leukemia | Active, Not Recruiting | 2026-09-16 |
| NCT02503423 | Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | Solid Tumors | Active, Not Recruiting | 2026-03-20 |
| Phase 1 | ||||
| NCT07691606 | A Study of ARC-02 in B-cell NHL | B-cell Non Hodgkin Lymphoma | Recruiting | 2026-08-26 |
| NCT04953897 | Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in… | Acute Myeloid Leukemia | Recruiting | 2026-05-28 |
| NCT04953910 | Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in… | Acute Myeloid Leukemia | Recruiting | 2026-05-28 |
Acute Myeloid Leukemia (AML) (5) · Leukemia (5) · Myelodysplastic Syndromes (MDS) (4) · MDS/MPN Overlap (2) · Non-Small Cell Lung Cancer (NSCLC) (2) · Cholangiocarcinoma (1) · Esophageal Cancer (1) · Lung Cancer (1) · Non-Hodgkin Lymphoma (1) · Pancreatic Cancer (1)